Yaşa Bağlı Makula Dejenerasyonunda Fotodinamik Tedavi

1. Smyth RJ, Nguyen K, Ahn SS, et al. The effects of photophrin on human Tenon's capsule fibroblasts in vitro. J Ocular Pharmacol 1993;9:171-8.
2. Jampel HD, Jabs DA, Quigley HA. Trabeculectomy with 5-fluorouracil for adult
inflammatory glaucoma. Am J Ophthalmol 1990;109:168-73.
3. Dougherty TJ, Marcus SL. Photodynamic therapy. Eur J Cancer 1992;28:1734-42.
4. Weissgold DJ, Hu LK, Gragoudas ES, et al. Photodynamic therapy (PDT) of pigmented choroidal melanoma via a trans-scleral approach. Invest Ophthalmol Vis Sci 1996;37:(S)123. (Abstract no 588.)
5. Moshfeghi DM, Peyman GA, Khoobehi B, et al. Photodynamic occlusion of retinal vessels using tin ethyl etiopurin (SnET2): an efficacy study. Invest Ophthalmol Vis Sci 1995;36:(S)115. (Abstract no 564.)
6. Cox KW, Shepperd JD, Lattanzio FA, et al. Photodynamic therapy of corneal neovascularization using topical dihematoporphyrin ester. Invest Ophthalmol Vis Sci 1997;38:(S)512. (Abstract no 2369.)
7. Dacheux R, Guidry C. Cellular photoablation as a therapy to control proliferative vitreoretinopathy: in vitro studies. Invest Ophthalmol Vis Sci 1995;36:(S)751.
(Abstract no 3476.)
8. Hill RA, Crean DH, Doiron DR, et al. Photodynamic therapy for antifibrosis in a rabbit model of filtration surgery. Ophthalmic Surg Lasers 1997;28:574-81
9. Manyak MJ, Russo A, Smith PD, et al. Photodynamic therapy. J Clin Oncol
1988;6:380-91.
10. Husain D, Miller JW. Photodynamic therapy of exudative age-related macular degeneration. Sem Ophthalmol 1997;12:14-25.
11. Roberts WG, Hasan T. Role of neovasculature and vascular permeability on the tumor retention of photodynamic agents. Cancer Res 1992;52:924-30.
12. Zhou C. Mechanisms of tumor necrosis induced by photodynamic therapy. J
Photochem Photobiol B 1989;3:299-318.
13. Ciulla TA, Danis RP, Haris A. Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol 1998; 43: 134-46.
14. Soubrane G, Bressler NM. Treatment of subfoveal choroidal neovascularisation in age-related macular degeneration-focus on clinical application of verteporfin
photodynamic therapy. Br J Ophthalmol 2001; 85: 483-95.
15. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Resuts of a randomized
clinical trial. Arch Ophthalmol 1991; 109: 1220-31.
16. Schimidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology
1994; 101: 1953-61.
17. Allison BA, Pritchard PH, Levy JG. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br J Cancer 1994;69:833-39.
18. Schmidt-Erfurth U, Hasan T, Schomacker K, et al. In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg Med 1995;17:178-88.
19. Richter AM, Kelly B, Chow J, et al. Preliminary studies on a more effective phototoxic agent than hemotoporphyrin. J Natl Cancer Inst 1987; 79: 1327-32.
20. Levy JG, Chan A, Strong HA. The clinical status of benzoporphyrin derivative. SPIE
1996; 2625: 86-95.
21. Husain D, Miller JW, Michaud N, et al. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal
neovascularization. Arch Ophthalmol 1996;114:978-85.
22. Schmidt-Erfurth U, Birngruber R, Hasan T. Photodynamic therapy in ocular vascular
disease. Laser Physics 1998;8:191-8.
23. Aveline B, Hasan T, Redmond RW. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem Photobiol
1994;59:328-35.
24. Husain D, Kramer M, Michaud N, et al. Photodynamic therapy (PDT) of experimental choroidal neovascularization (CNV) using benzoporphyrin derivative (BPD-MA): dye delivery and treatment parameters. Invest Ophthalmol Vis Sci
1995;36:S225.
25. Gaffney J, West D, Arnold F, et al. Differences in the uptake of modified low density lipoproteins by tissue cultured endothelial cells. J Cell Sci 1985;79:317-25.
26. Fogelman AM, Berliner JA, Van Lenten BJ, et al. Lipoprotein receptors and
endothelial cells. Sem Thromb Hemost 1988;14:206-9.
27. Kramer M, Kenney AG, Delori F, et al. Imaging of experimental choroidal neovascularization (CNV) using liposomal benzoporphyrin derivative mono-acid
(BPD-MA) angiography. Invest Ophthalmol Vis Sci 1995;36:S236.
28. Schmidt-Erfurth U, Bauman W, Gragoudas E, et al. Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin.
Ophthalmology 1994;101:89-99.
29. Haimovici R, Kramer M, Miller JW, et al. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Curr Eye Res 1997;16:83-90.
30. Kramer M, Miller JW, Michaud N, et al. Liposomal benzoporphyrin derivative verteporfin in photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 1996;103:427-38.
31. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000; 45: 195-214.
32. Scott LJ, Goa KL. Verteporfin. Drugs and Ageing 2000; 16(2): 139-47.
33. Schmidt-Erfurth U, Hasan T, Flotte T, et al. Photodynamic therapy of experimental intraocular melanoma using benzoporphyrin lipoprotein. Ophthalmologe
1994;91:348-56.
34. Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch
Ophthalmol 1995;113:810-18.
35. Husain D, Kramer M, Kenny AG, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 1999;40:2322-31.
36. Reinke MH, Canakis C, Husain D, et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology
1999;106:1915-23.
37. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol
1999;117:1161-73.
38. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of retreatments in a phase 1 and 2 study. Arch Ophthalmol
1999;117:1177-87.
39. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials TAP Report 1. Arch Ophthalmol 1999;117:1329-45.
40. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials- TAP Report Arch Ophthalmol 2001; 119: 198-207.
41. Kostenich G, Orenstein A, Roitman L, et al. In vivo photodynamic therapy with the new near-IR absorbing water soluble photosensitizer lutetium texaphyrin and a high intensity pulsed light delivery system. J Photochem Photobiol B 1997;39:36-42.
42. Graham KB, Arbour JD, Connolly EJ, et al. Digital angiography using lutetium texaphyrin in a monkey model of choroidal neovascularization. Invest Ophthalmol Vis Sci 1999;40:S402.
43. Primbs GB, Casey R, Lin GC, et al. Photodynamic therapy of corneal neovascularization using tin ethyl etiopurpurin (SnET2). Invest Ophthalmol Vis Sci
1997;38:S702.
44. Thomas EL, Rosen R, Murphy R, et al. Purlytin (SnET2)-photodynamic therapy produces closure of subfoveal choroidal neovascularization in humans. Invest
Ophthalmol Vis Sci 1998;39:S242.
45. Thomas EL, Rosen R Murphy R et al. Visual acuity stabilizes after a single treatment with SnET2 photodynamic therapy in patients with subfoveal choroidal
neovascularization. Invest Ophthalmol Vis Sci 1999;40:S401.
46. Moshfeghi DM, Peyman GA, Kazi AA, et al. Mono-L-aspartyl chlorin e6 (NPe6) angiography of the retina in pigmented rats, rabbits, and monkeys. Invest Ophthalmol
Vis Sci 1999;40:S322.
47. Wong Kee Song L-M, Wang KK, Zinsmeister AR Mono-L-aspartyl chlorin e6 (Npe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model. Cancer 1998;82:421-7.